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ABSTRACT 
Background: Intravitreal vascular endothelial growth factor (VEGF) inhibitors represent the mainstay of neovascular age-
related macular degeneration (nAMD) treatment. Although bevacizumab has been the first anti-VEGF used in ophthalmology, 
it is unlicensed for intraocular use. However, the favourable cost-benefit balance has favoured its widespread use. We aimed 
to present relevant literature regarding the safety profile and the regulatory issues of intravitreal bevacizumab use.  
Methods: In this narrative review we report relevant studies regarding the safety profile of intravitreal bevacizumab. Expert 
commentary is provided and an overview of the current scenario and possible future directions discussed. 
Results: Randomized controlled trials have demonstrated that bevacizumab is not inferior to the licensed anti-VEGF agents 
showing similar efficacy and safety profiles. However, a significant debate on the regulatory issues of intravitreal bevacizumab 
used as ‘off label’ first-line treatment in nAMD still persists. Recently, the Regional Health System of Lombardia in Italy decided 
to only cover the expenses of bevacizumab, forcing clinicians to use bevacizumab as the first choice in the treatment of nAMD. 
Issues about the practical implications of this decision are discussed. 
Conclusion: The use of intravitreal bevacizumab as first-line therapy in nAMD remains controversial. Many differences in the 
regulatory aspects still persist among the European countries and sometimes within the same countries, like Italy. Of note the 
clinical scenario will be modified in future by the introduction of newly developed anti-VEGF agents and anti-VEGF biosimilars. 
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INTRODUCTION
Intravitreal anti-vascular endothelial growth factor (anti-
VEGF) agents currently represent the mainstay of 
neovascular age-related macular degeneration (nAMD) 
treatment [1-3]. In Europe, there are three available anti-
VEGF agents for intravitreal use, namely bevacizumab 
(Avastin, Genentech Inc./Roche), ranibizumab 
(Lucentis, Genentech Inc./Novartis) and aflibercept 
(Eylea, Regeneron/Bayer) [4]. The first evidences of 
activity in nAMD have been reported with systemic 
bevacizumab [5], which has been originally approved for 
the metastatic colorectal cancer and advanced breast 
cancer treatment [6].  
Although bevacizumab has never taken the on label 
patent for intraocular use, its widespread use in the 
treatment of nAMD has been encouraged by its 
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than ranibizumab and aflibercept [7], hence rapidly gained 
popularity among the ophthalmologists, even after the 
registration of ranibizumab and aflibercept for intravitreal 
use in nAMD [8, 9].  
In Italy the Ministry of Health is accountable for the Italian 
National Health System (Sistema Sanitario Nazionale - 
SSN) planning and for the coordination of regional 
activities, aimed at guaranteeing the same essential levels 
of care in all areas of the country. Regions are called to 
define their own health plans to organize health services 
delivery within their own territory according to the central 
government planning [10]. The Italian Medicine Agency 
(Agenzia Italiana del Farmaco - AIFA) is competent in the 
regulation of both approved drugs and off-label 
treatment. In 2018 the European Justice Court judgment 
expressed no objection to the use of bevacizumab for the 
treatment of retinal diseases [11]. Following the 
aforementioned judgement, in July 2019 the Region of 
Lombardia, one of the wealthiest and populated Italian 
regions, ruled to reimburse a fixed amount of 55,60 EURO 
for each injection in patients with nAMD, irrespective of 
the anti-VEGF agent used [12]. The decision has been 
supported by the evidence of similarity of the currently 
available anti-VEGF drugs in terms of safety and efficacy in 
nAMD, with a remarkable cost effectiveness in favour of 
bevacizumab [12, 13].  
Ophthalmologists are formally free to choose either of the 
anti-VEGF agents available. However, since 55,60 EURO 
can only cover the expenses of bevacizumab, this decision 
has forced hospitals and healthcare organizations in 
Lombardia to switch to bevacizumab as first choice in 
nAMD. A few years before this decree in Lombardia, the 
Italian Regions of Emilia-Romagna and Veneto had been 
allowed by the AIFA to use bevacizumab for nAMD in 
public hospitals [14, 15]. However, unlike the current 
scenario in Lombardia, the clinicians of Emilia-Romagna 
and Veneto have the option to get the on label anti-VEGF 
agents (ranibizumab and aflibercept) funded as the first-
line treatment in nAMD. 
The recent decision of the Regional Health System of 
Lombardia has led us to briefly review the safety profile of 
bevacizumab and to give an overview about the 
pharmacology, regulatory issues and the pros and cons of 
intravitreal bevacizumab use in nAMD. 
METHODS 
This is a narrative review based on a PubMed search 
through April 2020 aimed at reporting relevant literature 
regarding the safety profile and the regulatory issues of 
intravitreal bevacizumab use. Reference lists were 
checked to identify additional relevant studies. Expert 
commentary is provided and an overview of the current 
scenario and possible future directions discussed. 
DISCUSSION 
Pharmacology and Safety Profile  
Intravitreal anti-VEGF drugs pass in to the systemic 
circulation and are able to decrease the plasma-free VEGF 
[8], theoretically increasing the risk of systemic 
thromboembolic events [16]. Of note, anti-VEGF 
molecules containing the antibody fragment crystallizable 
(Fc) region (bevacizumab and aflibercept) can remain in 
circulation longer than the anti-VEGF agents without the 
Fc region (ranibizumab) [8], resulting a longer half-life, 
slower systemic catabolism and a stronger decrease of 
plasma-free VEGF.  
Several randomized controlled trials (RCTs) such as the 
Comparison of Age-related macular degeneration 
Treatments Trials (CATT) study and the alternative 
treatments to Inhibit VEGF in Age-related choroidal 
Neovascularization (IVAN) study, have demonstrated 
that bevacizumab is not inferior to ranibizumab in the 
treatment of nAMD showing similar efficacy and safety 
profiles [17-21]. In 2014 a Cochrane systematic review of 
non-industry sponsored RCTs showed no statistically 
significant differences in deaths due to thromboembolic 
events such as stroke or myocardial infarction between  
bevacizumab and ranibizumab [22].  
On the other hand, the risk of thromboembolic events 
could be underestimated in real life setting compared to 
RCTs data. Indeed, patients with history of stroke or 
myocardial infarction are usually excluded from 
sponsored multicentre clinical trials [16]. Moreover RCTs 
are designed to primarily assess the efficacy of drugs 
rather than their safety [16]. Thus, to date it is not possible 
to definitely answer the question whether there is a 
definite increased cardiovascular risk of using anti-VEGF 
agents in such patients who are eligible for treatment. 
However, pharmacokinetic/pharmacodynamic and safety 
data reported in both clinical trials and real world studies 
provide robust evidence that systemic events due to 
intravitreal injections are very unlikely [23] with no 
evidence of increased risk of death in patients [24].  
At present the vials of bevacizumab are fractioned by the 
hospital pharmacies under sterile conditions and 
thereafter sent for the intravitreal use. Conversely, the 
vials of ranibizumab and aflibercept are prepared by an 
automated production line acquired directly from the 
manufacturer. Therefore, concern has been raised about 
possible microbial contamination during the 
compounding procedures for bevacizumab, resulting in 
higher levels of infectious endophthalmitis [25]. However, 
subsequent large data have showed that the rate of 
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endophthalmitis with the pharmacy-compounded 
bevacizumab is not superior to single-use vials of 
ranibizumab [26]. Knowledge based on scientific evidence 
must guide our medical decisions and not the marketing 
status [27]. At present, there is no definite evidence-based 
reason not to use intravitreal bevacizumab because of 
systemic safety issues [7, 16] (Table 1). 
 
Table 1: A Summary of Safety Profile of Intravitreal 
Bevacizumab Use in Ophthalmology 
Pharmacology and Safety Profile of Intravitreal Bevacizumab. 
Intravitreal anti-VEGF drugs pass into the systemic 
circulation and are able to decrease the plasma-free VEGF. 
RCTs showed no statistically significant differences in 
mortality rate due to thromboembolic events between 
bevacizumab and ranibizumab. 
CATT and IVAN studies demonstrated that bevacizumab is 
not inferior to ranibizumab in the treatment of nAMD. 
The rate of endophthalmitis with the pharmacy-
compounded bevacizumab is not superior to the single-use 
vials of ranibizumab. 
Abbreviations: CATT: Comparison of Age-related macular degeneration 
Treatments Trials; IVAN: Inhibit VEGF in Age-related choroidal 
Neovascularization; nAMD: neovascular age-related macular 
degeneration; RCTs: randomized controlled trials; VEGF: vascular 
endothelial growth factor. 
 
Regulatory Issues 
In spite of the good safety profile, over the past years, the 
use of bevacizumab as first-line therapy in nAMD has been 
discouraged by many health authorities and National 
health systems across the world [7]. Indeed, the 
prescription of bevacizumab has always been limited in 
countries other than the United States [28, 29]. However, 
the increasing demand of anti-VEGF treatment in nAMD 
with the resulting cost burden has led the European 
countries to a more liberal attitude on the use of the less 
expensive bevacizumab [7]. The use of an off-label drug in 
the presence of on-label drugs is controversial because of 
its regulatory and legal implications. A simple solution 
would have been the registration of bevacizumab for 
intraocular use. Roche and Genentech developed both 
bevacizumab and ranibizumab, respectively. As far as we 
know, Roche has never requested the license for 
intraocular use of bevacizumab.  
Over the last decade we have assisted to a significant 
debate on the use of intravitreal bevacizumab in 
ophthalmology. In Italy, like in many other European 
countries, bevacizumab has been extensively used before 
the introduction of ranibizumab. Indeed, the Italian “off-
label law” N° 648/1996 [30] allows the use of off-label 
drugs in absence of an on-label option and the use of 
bevacizumab was justified by the evidence that it was safe 
and more effective than the established treatment of 
nAMD at that time, namely photodynamic therapy [5, 31]. 
Once ranibizumab had been marketed and approved for 
nAMD, in Italy the use of bevacizumab has been at first 
dismissed, then reintroduced with an annex of the off-
label law 648/1996 and thereafter dismissed again by the 
AIFA in 2012 [32]. 
Meanwhile, the Italian Competition Authority (Autorità 
Garante della Concorrenza e del Mercato - AGCM) 
sentenced against Roche and Novartis, respectively the 
owners of bevacizumab and ranibizumab, for raising 
unmotivated concerns about the safety of bevacizumab 
while promoting the more expensive ranibizumab [33]. 
AGCM recalled the assessment of the European Medical 
Agency (EMA) which did not find any greater systemic risk 
in the intravitreal use of bevacizumab compared to 
ranibizumab [34]. In 2017, the AIFA has reintroduced 
intravitreal bevacizumab in the list of the off-label drugs 
reimbursed by the SSN [35]. In November 2018 the 
European Court of Justice sentenced that each Country 
has the authority to allow the use of an off-label drug for 
social and economic reasons [33, 36, 37] accepting the 
request submitted by the AIFA in 2017. 
On these grounds, in July 2019 the Local Health Authority 
of Lombardia decided for a massive change, economically 
introducing bevacizumab as the first-line treatment of 
nAMD with an authoritative and unprecedented 
straightforward policy decision in Italy [12]. It has taken a 
couple of months to see a “massive switch” to 
bevacizumab for nearly all patients with nAMD in the 
region.  
The Regional Health System of Lombardia tracked the 
prescription of the intravitreal anti-VEGF agents in 
Lombardia before and after the decree of July 2019 [12]. 
Before the decree, ranibizumab, aflibercept and 
bevacizumab accounted for 63%, 37% and less than 1% of 
the total number of injections, respectively. In November 
2019, with the full application of the decree, the 
prescription of anti-VEGF drugs significantly changed in 
favour of bevacizumab as ranibizumab, aflibercept and 
bevacizumab accounted for 17%, 8,8% and 73,2% of the 
total number of injections, respectively [38]. Of note, the 
latter data include anti-VEGF agents prescribed also for 
conditions other than nAMD, namely diabetic macular 
edema, macular edema secondary to retinal vein 
occlusions, and any choroidal neovascularization-
associated condition.  
Expert Commentary 
While this decree in Lombardia will save a large amount of 
health care funds, it possibly goes against the concept of 
personalized medicine based on patients individual needs 
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by limiting the options of the clinicians in the choice of the 
most appropriate anti-VEGF agent. It is indeed impressive 
how strong may be the impact of politics, mainly driven by 
economic considerations, on the clinical decisions and 
ultimately on the health of patients.  
Significant issues have been raised about the practical 
implications of this decree. First, at present only a limited 
number of hospital pharmacies in Lombardia provide 
bevacizumab for intravitreal use. This has led to an 
overload of these hospitals with an unexpected number of 
patients who were already under treatment with either 
ranibizumab or aflibercept in other centers. Second, some 
patients who poorly respond to one anti-VEGF agent may 
possibly benefit from switching to another anti-VEGF 
agent [39, 40]. Clinicians and the Lombardia Region 
authorities should come to an agreement about the 
switching criteria to the other anti-VEGFs in case of poor 
response to bevacizumab.  
Current trends and future directions 
In the current literature there is little evidence on such a 
massive switch driven by a policy decision and therefore 
this scenario may represent an opportunity to collect 
more information about the clinical course of such 
patients. We would like to mention the case of Sweden 
where a switch to bevacizumab was imposed by their 
health authority. While no significant drop of visual acuity 
was reported after the switch, 18-19% of patients were 
found to be non-responder to bevacizumab and switched 
back to ranibizumab or aflibercept [41]. Different 
attitudes towards the off-label use of bevacizumab in 
nAMD across the European Nations have been shown by 
a recent report [42]; indeed in Europe the use of 
bevacizumab in nAMD may vary considerably, ranging 
from non-existent (Switzerland, Hungary, Denmark) to 
very frequent (Romania, Bulgaria, Finland, Ireland, 
Netherlands). Moreover, large disparities within single 
countries, resulting from different organization of the 
National Health Systems and regional autonomies have 
been reported [42]. 
In the United Kingdom, until recent years, the General 
Medical Council and the National Institute for Health and 
Care Excellence (NICE) guidelines have not encouraged 
ophthalmologists to use bevacizumab in nAMD [43]. 
However, in September 2018, an association of 12 Local 
Health Authorities of the North England (namely the 
Clinical Commissioning Groups of the National Health 
Service) have obtained the legal right to use bevacizumab 
as the first-line treatment in nAMD [44].  
Despite the favourable reports of the EMA about 
bevacizumab in terms of efficacy, safety and cost profiles, 
the attitude of the European health authorities about the 
use of bevacizumab in nAMD is still heterogeneous [42].  
It should be noted that in future the patents of 
ranibizumab and aflibercept will expire and biosimilars 
molecules will be available for the treatment of nAMD and 
other retinal diseases and will possibly complicate the 
current scenario and its regulatory issues [45, 46].  
Moreover, a newly developed anti-VEGF agent, 
brolucizumab (Beovu®, Novartis), has been approved by 
the U.S. Food and Drug Administration and by the EMA for 
the treatment of nAMD [47]. The main advantage of 
Brolucizumab over the other anti-VEGFs would be the 
longer durability, thus having the potential to reduce the 
treatment burden [48, 49]. 
CONCLUSION  
After a decade of debate about the use of on- and off-label 
drugs, the use of intravitreal bevacizumab as first-line 
therapy in nAMD remains controversial, in spite of its 
efficacy and safety profile. Over the last few years, the 
financial sustainability of the government-funded health 
care systems of the European countries has been 
challenged. The health care authorities will play a crucial 
role in exploring new ways to guarantee an effective 
therapy for nAMD with affordable costs. In this regard, 
many differences in the regulatory aspects still persist 
among the European countries and sometimes within the 
same countries, like Italy [42]. Approval of new drugs and 
negotiation of their cost with the pharmaceutical 
companies will pose additional questions. Finally, the 
clinical scenario will be modified in future by the 
introduction of anti-VEGF biosimilars, which have the 
potential to fill the gap between the on-label and costlier 
anti-VEGFs and the off-label and cheaper bevacizumab 
[45, 46].  
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